SecBot SecBot

VRXA

Veraxa Biotech AG - Post de-SPAC
Nasdaq· Pharmaceutical Preparations· Inc. V8· CIK 0002079109 Biotech & Drug Discovery
$0.9800 −0.02 (−2.00%)
Oct 26 4:00 PM ET · prev $1.00
Market cap
$145.7M
Micro cap
1 year
−90.7%
from $10.49 · Oct 27
30 days
−28.5%
from $1.37
52-week range
$0.9800–24.79
at the low
Avg volume 20D
293.6K
Oct 9 spike 1.86M
Short interest
🔒 Subscribers only
Insider net
+$125.4K
4 buyers · 0 sellers · 12 mo
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 4 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/8
Strongest NEUTRAL Veraxa Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the World ADC…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $125.4K at an average $1.38. No open-market sales. Price is 29% below their cost.

  • TrendDOWNTREND

    30% below its 50-day average. New closing low $0.9800 on Oct 26.

Who's buying

13F
Top holderSharesValue
UBS Group AG157,237$295.6K
GEODE CAPITAL MANAGEMENT, LLC119,767$225.2K
HRT FINANCIAL LP18,874$35.0K
SUSQUEHANNA INTERNATIONAL GROUP, LLP10,833$20.4K
PICTON MAHONEY ASSET MANAGEMENT175,000$19.3K
WOLVERINE ASSET MANAGEMENT LLC1,748$3.3K
JPMORGAN CHASE & CO396$859.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 Insider
Ziegler Christoph Samuel bought 30,000 shares
Director @ $1.09 ($32.7K)
Oct 15, 2026 SEC
Veraxa Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the World ADC Congress…
6-K — Impact 4/10
Sep 10, 2026 Insider
Hosseinion Warren bought 6,024 shares
Director @ $1.67 ($10.1K)
Sep 4, 2026 SEC
Veraxa Biotech AG appointed Raju Willener as CFO effective September 4, 2026. Mr. Willener brings over 30 years of…
6-K — Impact 3/10
Sep 4, 2026 Press
Veraxa Biotech announced the appointment of Raju Willener as CFO, effective immediately. Willener brings over 30 years…
Impact 2/10
Sep 4, 2026 Announcement
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Mr. Willener brings more than three decades of global capital markets and corporate finance experien
Aug 27, 2026 Insider
Baumann Oliver Rolf bought 50,000 shares
Director @ $1.50 ($75.0K)
Aug 24, 2026 SEC
Veraxa Biotech announced initial positive in vitro proof-of-concept results from its strategic research collaboration…
6-K — Impact 3/10

Insider ledger

Form 4
$125.4K
bought · 4 insiders
$0
sold · 0 insiders
−28.9%
vs their $1.38 cost
DateInsiderTypeValue
Oct 20, 2026
Ziegler Christoph Samuel
Director
BUY$32.7K
Sep 10, 2026
Hosseinion Warren
Director
BUY$10.1K
Aug 27, 2026
Baumann Oliver Rolf
Director
BUY$75.0K
Aug 27, 2026
Antz Christoph Rudiger
Chief Executive Officer
BUY$7.7K

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 4, 2026
Announcement
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s…
Jul 27, 2026
Announcement
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical…
Jul 23, 2026
Announcement
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer…
Jul 13, 2026
Announcement
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
VERAXA Biotech initiates a collaboration with Ardigen SA to optimize cancer target pair selection for growing BiTAC® pipeline.
Jul 10, 2026
Announcement
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
VERAXA Biotech AG today announced the appointment of Carl von Halem as as Interim Chief Financial Officer.

SecBot reports

11 filings · 5 press releases · 0 bullish · 5 bearish · 6 neutral
All VRXA filing & press-release reports (16)